Francisco Bonilla, MD
Allergy & Immunology · Leominster, MANPI 1245298215
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $141,060 of the $188,351 with a category attached, or 74.9%. 38 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 44.0% of the total. Reporting peaked in 2022 at $58,433 and has fallen 96.6% since, to $1,963 in 2025. Among allergy & immunology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 516 payments — averaging $365.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$83K
- Amgen$66K
- Shire North American Group Inc$25K
- Grifols USA, LLC$7K
- Pfizer$2K
- AstraZeneca$1K
- plus $5K from 32 others
Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Consulting fees$22,26812%
- Speaking & faculty fees$141,06075%
- Travel & lodging$13,4627%
- Food & beverage$11,4286%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 127 | $82,958 |
| Amgen(2 entities) | 57 | $65,589 |
| Shire North American Group Inc | 39 | $25,265 |
| Grifols USA, LLC | 20 | $6,593 |
| Pfizer | 32 | $2,212 |
| AstraZeneca | 48 | $1,052 |
| Pharming Healthcare, Inc. | 10 | $724 |
| GSK | 37 | $626 |
| Regeneron Healthcare Solutions, Inc. | 29 | $624 |
| CSL Behring | 20 | $461 |
| Sanofi | 18 | $431 |
| Novartis | 10 | $218 |
| GC Biopharma USA, Inc. | 8 | $193 |
| Kaleo, Inc. | 7 | $156 |
| Grifols Shared Services North America, Inc. | 1 | $138 |
| Blueprint Medicines Corporation | 5 | $117 |
| AbbVie | 4 | $104 |
| Teva Pharmaceuticals USA, Inc. | 4 | $101 |
| Genentech USA, Inc. | 5 | $87 |
| Incyte Corporation | 3 | $75 |
| Galderma Laboratories, L.p. | 4 | $72 |
| Lilly USA, LLC | 3 | $65 |
| Bio Products Laboratory USA, Inc. | 4 | $62 |
| Kedrion Biopharma, Inc. | 3 | $60 |
| Biocryst US Sales Co., LLC | 2 | $53 |
| Octapharma USA, Inc. | 2 | $46 |
| Verona Pharma, Inc. | 2 | $45 |
| Mylan Specialty L.p. | 1 | $38 |
| Cycle Pharmaceuticals Inc | 2 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Greer Laboratories, Inc. | 1 | $22 |
| LEO Pharma Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Invivyd Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
| Alk-abello, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIMMUNE$65,204
- HYQVIA$41,953
- CUVITRU$37,181
- Xembify$6,413
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$1,665
How this compares
$188,351 in reported general payments places this provider in the 95th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 37 | $177,253 |
| Dupixent PenDupilumab | 23 | $94,117 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $93,572 |
| XolairOmalizumab | 12 | $31,577 |
| Arnuity ElliptaFluticasone Furoate | 58 | $17,804 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $14,301 |
| Epinephrine | 79 | $10,707 |
| Pulmicort FlexhalerBudesonide | 28 | $9,077 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,157 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $6,619 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,011 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $4,292 |
| Wixela InhubFluticasone Propion/Salmeterol | 32 | $4,150 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $3,022 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $82,958 | $177,25337 claims |
| CSL BehringHizentra | $461 | $93,57214 claims |
| GSKArnuity Ellipta, Breo Ellipta, Trelegy Ellipta | $626 | $40,26293 claims |
| AstraZenecaPulmicort Flexhaler | $1,052 | $9,07728 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Acyclovir | $101 | $4,72323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Leominster
- David RiesterLeominster$13K
- Jordan ScottLeominster$13K
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Maria CastellsGardner$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.